-
[大包装]170277-31-3,英夫利昔单抗,Infliximab
-
[工业级供应]2-氨基-3’-氯联苯400743-82-0
-
[原料药研发]1672665-49-4,PT-2385
-
[KG级]异丙基-β-D-硫代半乳糖苷(IPTG),98%
-
[KG级]56066-63-8,阿地普林,5-[(4-dimethylamino-3,5-dimethoxy-phenyl)methyl]pyrimidine-2,4-diamine
-
[中试供应]152658-17-8,盐酸纳呋拉啡, Nalfurafine
-
[工业级供应]LOBAPLATINcas:135558-11-1乐铂
-
[公斤级中间体]西司他丁钠81129-83-1Cilastatin sodium
-
[工业级供应]2138299-33-7, DIABZI STING AGONIST-1
-
[KG级]西司他丁钠81129-83-1Cilastatin sodium
-
[公斤级中间体]1853236-69-7
-
[新药中间体放大]129425-81-6,MSA-2
-
[大包装]1207456-01-6 (8S,9R)-5-氟-8-(4-氟苯基)-2,7,8,9-四氢-9-(1-甲基-1H-1,2,4-三唑-5-基)-3H-吡啶并[4,3,2-DE]酞嗪-3-酮
-
[原料药研发]二甲胺水
-
[KG级]异丙基-β-D-硫代半乳糖苷(IPTG),98%
-
[药物分子开发]六氟异丙醇920-66-1
-
[公斤级中间体]210101-16-9, CONIVAPTAN
-
[批量合成]比阿培南Biapenem120410-24-4
-
[KG级]西司他丁钠81129-83-1Cilastatin sodium
-
[工业级供应]2-氨基-3’-氯联苯400743-82-0